13 March 2026
Johnson & Johnson Reports Positive Phase 1 Results for Erda-iDRS in Bladder Cancer
Erda-iDRS shows safety and efficacy in Phase 1 for intermediate-risk bladder cancer, with high complete response rates and ongoing Phase 2 and 3 studies.
